Sanofi (SNYNF) announced it has entered into exclusive negotiations to sell a 50 percent controlling stake in its consumer healthcare business, Opella, to private equity firm CD&R. The valuation of Opella is based on an enterprise value of 16 billion euros.
Sanofi will remain a significant shareholder, supporting Opella in its future growth and path to independence. Bpifrance is expected to participate as a minority shareholder with an approximate 2% stake.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com